Chiron Tifacogin Needs One Pivotal Study For Community Acquired Pneumonia
Executive Summary
Chiron will need only a single pivotal trial for approval of its tissue factor pathway inhibitor tifacogin as a treatment for severe community acquired pneumonia
You may also be interested in...
Novartis Would Get Anti-Infective, Oncologic Pipeline Drugs In Chiron Deal
Novartis' proposed acquisition of Chiron would give the company anti-cancer and anti-infective molecules to complement its oncologic portfolio and infectious disease pipeline
Novartis Would Get Anti-Infective, Oncologic Pipeline Drugs In Chiron Deal
Novartis' proposed acquisition of Chiron would give the company anti-cancer and anti-infective molecules to complement its oncologic portfolio and infectious disease pipeline
Chiron To Distribute Fluvirin Directly To Providers For 2004-2005 Flu Season
Chiron plans to distribute its injectable influenza vaccine Fluvirin directly to some providers this year to increase its profit margins